(Q34536138)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11851828%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

review article

1 reference

title

Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11851828%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

main subject

hepatocellular carcinoma

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11851828%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

author name string

M Okuno

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11851828%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

H Moriwaki

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11851828%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

publication date

1 December 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11851828%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastroenterology and Hepatology

7 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11851828%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11851828%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11851828%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

page(s)

1329-1335

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11851828%20AND%20SRC:MED&resulttype=core&format=json

Risk factors for the rising rates of primary liver cancer in the United States.

7 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Different clinicopathological features of hepatocellular carcinoma in relation to causative agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Abnormal structure and expression of p53 gene in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

The long term efficacy of glycyrrhizin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Cytokine therapeutics: lessons from interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

The role of STATs in transcriptional control and their impact on cellular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Reduced retinoid content in hepatocellular carcinoma with special reference to alcohol consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

A new retinoic acid receptor identified from a hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Retinoid-induced apoptosis in normal and neoplastic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Regulation of interferon and retinoic acid-induced cell death activation through thioredoxin reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02634.X